Skip to main content
. Author manuscript; available in PMC: 2022 Apr 15.
Published in final edited form as: Neurosurg Focus. 2022 Feb;52(2):E9. doi: 10.3171/2021.11.FOCUS21571

Figure 1.

Figure 1.

A summary of multiomics approaches to characterize neuroimmune interactions in degenerative disc disease and glioblastoma multiforme. (1A) Proteomics can be used to identify susceptibilities of GBM to immunotherapy based on protein-protein network analysis, (1B) Metabolomics can identify metabolites that modulate immune interactions after aSAH, and (1C) Transcriptomics can identify differentially expressed genes in immune signaling pathways that drive DDD progression. Figure 1 created using BioRender.com.